Kane Biotech EBITDA par action

Que fait Kane Biotech ? Kane Biotech, Inc. generates revenue through its portfolio of biotechnology products designed to prevent and remove microbial biofilms. The company commercializes StrixNB, DispersinB, Aledex, bluestem, silkstem, goldstem, coactiv+, and DermaKB Biofilm, with specific focus on the Wound Care & Surgical division developing DispersinB for chronic wound care. The bluestem product line targets animal health markets with water additives, chews, spray, and dental wipes, while Coactiv+ and DispersinB Gel are in development for antimicrobial wound rinse and prosthetic joint infection applications. Additional products include Scalp Detoxifier, Shampoo, and Shampoo Bars for consumer use. Kane Biotech serves animal health markets through its bluestem product line, which includes water additives, chews, spray, and dental wipes. The Wound Care & Surgical division targets medical applications, focusing on DispersinB for chronic wounds and developing Coactiv+ for antimicrobial wound rinse and surgical hydrogel. Consumer products like Scalp Detoxifier, Shampoo, and Shampoo Bars cater to personal care segments. The company's development-stage products such as Coactiv+ antimicrobial surgical hydrogel and DispersinB Gel for prosthetic joint infection represent future revenue streams. The company's primary markets include animal health for bluestem products, medical applications for Wound Care & Surgical division, and consumer personal care for Scalp Detoxifier and Shampoo products. DispersinB is central to the medical division, while bluestem dominates the animal health segment. Development-stage products like Coactiv+ and DispersinB Gel are positioned to address unmet needs in wound care and prosthetic infections, expanding the company's market reach into specialized medical and consumer health segments. Kane Biotech est l'une des entreprises les plus populaires sur Eulerpool.